File(s) not publicly available
Targeting tumor-stroma crosstalk: the example of the NT157 inhibitor
journal contribution
posted on 2023-06-08, 23:02 authored by T Rampias, R Favicchio, J Stebbing, Georgios GiamasGeorgios GiamasRecent clinical research has provided evidence that cancer progression and therapy resistance is driven not only by tumor’s genetic profile but also by complex paracrine interactions within the tumor microenvironment (TME). The role of TME in modulating tumor drug sensitivity is increasingly recognized and targeting TME has been the focus of novel therapeutic approaches. Two recent reports show that a new anti-cancer drug, the inhibitor NT157 has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stoma cells of TME leading to a decrease in cancer cell survival.
History
Publication status
- Published
Journal
OncogeneISSN
0950-9232Publisher
Nature Publishing GroupExternal DOI
Issue
20Volume
35Page range
2562-2564Department affiliated with
- Biochemistry Publications
Full text available
- No
Peer reviewed?
- Yes
Legacy Posted Date
2015-11-04Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC